1. Home
  2. APRE vs AIRE Comparison

APRE vs AIRE Comparison

Compare APRE & AIRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aprea Therapeutics Inc.

APRE

Aprea Therapeutics Inc.

HOLD

Current Price

$0.63

Market Cap

11.5M

Sector

Health Care

ML Signal

HOLD

Logo reAlpha Tech Corp.

AIRE

reAlpha Tech Corp.

HOLD

Current Price

$1.42

Market Cap

11.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
APRE
AIRE
Founded
2006
2021
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.5M
11.5M
IPO Year
2019
2023

Fundamental Metrics

Financial Performance
Metric
APRE
AIRE
Price
$0.63
$1.42
Analyst Decision
Strong Buy
Buy
Analyst Count
2
3
Target Price
$4.10
$1.30
AVG Volume (30 Days)
57.0K
64.8K
Earning Date
05-13-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
21.22
60.34
EPS
N/A
N/A
Revenue
N/A
$4,518,498.00
Revenue This Year
N/A
$129.06
Revenue Next Year
N/A
$83.72
P/E Ratio
N/A
N/A
Revenue Growth
N/A
376.42
52 Week Low
$0.55
$0.16
52 Week High
$1.93
$3.98

Technical Indicators

Market Signals
Indicator
APRE
AIRE
Relative Strength Index (RSI) 40.85 38.95
Support Level $0.57 $0.29
Resistance Level $0.83 $2.17
Average True Range (ATR) 0.06 0.17
MACD -0.01 -0.03
Stochastic Oscillator 34.44 17.45

Price Performance

Historical Comparison
APRE
AIRE

About APRE Aprea Therapeutics Inc.

Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.

About AIRE reAlpha Tech Corp.

ReAlpha Tech Corp is a real estate technology company. The group is engaged in an end-to-end commission-free homebuying platform. It develops and utilizes its artificial intelligence-focused technology stack to empower retail investor participation in short-term rental properties, which are real estate units listed for a rental term. It provides short-term rental investment opportunities to everyday investors. The company has developed technologies and tools that allow for the analysis of short-term rental properties using AI to provide insight into that property's potential profitability and ways to increase such profitability. The company's reportable segments are Homebuying Services and the Technology Services segment.

Share on Social Networks: